Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis

An antagonistic antibody, or a binding fragment thereof, which binds human TGF-beta 1, human TGF-beta 2 and human TGF-beta 3, having a heavy chain comprising the sequence given in SEQ ID NO:52, SEQ ID NO:59, SEQ ID NO:66, SEQ ID NO:73, SEQ ID NO:80, SEQ ID NO:87, SEQ ID NO:94, or SEQ ID NO:101 and a light chain comprising the sequence given in SEQ ID NO:38 or SEQ ID NO:45.

A process for the production of an antagonistic antibody, or a binding fragment thereof, which binds human TGF-beta 1, human TGF-beta 2 and human TGF-beta 3 comprising a heavy chain and a light chain, wherein the variable domain of the heavy chain comprises a CDR having the sequence given in SEQ ID NO:4 for CDR-H1, a CDR having the sequence given in SEQ ID NO:5 for CDR-H2 and a CDR having the sequence given in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:9 for CDR-H3, and wherein the variable domain of the light chain comprises a CDR having the sequence given in SEQ ID NO:1 for CDR-L1, a CDR having the sequence given in SEQ ID NO:2 for CDR-L2 and a CDR having the sequence given in SEQ ID NO:3 for CDR-L3, comprising culturing a host cell expressing said antibody and isolating said antibody.